

RPG LIFE SCIENCES LIMITED
Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

Rs. In Lakhs

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2016						
Particulars	3 months ended			6 months ended		Year ended
	30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016
	Unaudited			Unaudited		Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of Excise Duty)	7,638	8,523	6,720	16,161	13,370	27,454
(b) Other Operating Income	222	220	121	442	215	478
Total Income from Operations (Net)	7,860	8,743	6,841	16,603	13,585	27,932
2. Expenses						
(a) Cost of Materials Consumed	1,320	2,034	1,794	3,354	3,105	6,025
(b) Purchases of Stock-in-Trade	1,560	1,786	882	3,346	1,659	3,360
(c) Changes in Inventories of Finished Goods, Work-in- Progress and Stock-in-Trade	(44)	(750)	(432)	(794)	(142)	(241)
(d) Employee Benefits Expense	1,863	1,819	1,797	3,682	3,574	7,413
(e) Depreciation and Amortisation Expense	239	268	262	507	517	1,015
(f) Other Expenses	2,494	2,577	2,252	5,071	4,306	9,027
Total Expenses	7,432	7,734	6,555	15,166	13,019	26,599
3. Profit from Operations before Other Income, Finance Costs and Exceptional Items	428	1,009	286	1,437	566	1,333
4. Other Income	18	18	45	36	73	78
5. Profit from Ordinary Activities before Finance Costs and Exceptional Items	446	1,027	331	1,473	639	1,411
6. Finance Costs	18	40	75	58	169	249
7. Profit from Ordinary Activities after Finance Costs but before Exceptional Items	428	987	256	1,415	470	1,162
8. Exceptional Items - Profit on sale of Biotech Business Unit [Refer Note 5]	738	-	-	738	-	-
9. Profit from Ordinary Activities before Tax	1,166	987	256	2,153	470	1,162
10. Tax Expense						
a. Current Tax	250	213	61	463	97	224
b. MAT Credit Entitlement	(250)	(213)	(61)	(463)	(97)	(224)
c. Deferred Tax	141	-	-	141	-	-
11. Net Profit for the period	1,025	987	256	2,012	470	1,162
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						12,036
14. Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	6.20	5.97	1.55	12.17	2.84	7.03
(b) Diluted	6.20	5.97	1.55	12.17	2.84	7.03

Notes:

1. Standalone Statement of Assets and Liabilities

Particulars	(Rs. in lakhs)	
	As at 30.9.2016	As at 31.3.2016
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	14,048	12,036
Sub-total - Shareholders' Funds	15,371	13,359
2. Non-Current Liabilities		
(a) Long-term Borrowings	24	24
(b) Deferred Tax Liabilities (Net)	141	-
(c) Other Long-term Liabilities	263	261
(d) Long-term Provisions	185	199
Sub-total - Non-Current Liabilities	613	484
3. Current Liabilities		
(a) Short-term Borrowings	1,826	2,196
(b) Trade Payables	4,047	3,371
(c) Other Current Liabilities	766	1,017
(d) Short-term Provisions	320	96
Sub-total - Current Liabilities	6,959	6,680
TOTAL - EQUITY AND LIABILITIES	22,943	20,523
B ASSETS		
1. Non-Current Assets		
(a) Fixed Assets	9,737	11,085
(b) Long-term Loans and Advances	1,025	719
Sub-total - Non-Current Assets	10,762	11,804
2. Current Assets		
(a) Inventories	4,702	3,902
(b) Trade Receivables	4,774	3,699
(c) Cash and Bank Balances	1,863	80
(d) Short-term Loans and Advances	842	1,038
Sub-total - Current Assets	12,181	8,719
TOTAL - ASSETS	22,943	20,523

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 21st October, 2016.

3. The results for the quarter ended 30th September, 2016 have been subjected to limited review by the statutory auditors of the Company.

4. The Company is exclusively engaged in the pharmaceuticals segment.

5. Pursuant to the approval of the Board of Directors at their meeting held on May 26, 2016, the Company had entered into a Business Transfer Agreement dated May 26, 2016 with Intas Pharmaceuticals Limited for sale of Biotech Business Unit, as a going concern on a slump sale basis, at a consideration of Rs. 2,487 lakhs. The sale consideration has been received on July 6, 2016 (closing date). The gain realised from the aforesaid sale of Biotech Business Unit amounting to Rs. 738 lakhs has been disclosed as an exceptional item in the financial results. The same has been considered as discontinuing operations in accordance with Accounting Standard - 24 - "Discontinuing Operations" and the requisite information for Biotech Business Unit has been furnished hereunder;

Particulars	Rs. In Lakhs					
	3 months ended			6 months ended		Year ended
	30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016
		Unaudited				Audited
a) Net Sales	-	643	508	643	927	2,437
b) Direct Expenses	(7)	496	558	489	1,006	2,114
c) Profit/(Loss) from ordinary activities before tax	7	147	(50)	154	(79)	323
d) Tax Expense (net off MAT Credit Entitlement)	-	-	-	-	-	-
e) Net Profit/(Loss) from ordinary activities after tax (c-d)	7	147	(50)	154	(79)	323
f) Profit on sale of Biotech Business Unit	738	-	-	738	-	-
g) Tax Expense [net of MAT credit entitlement] on f) above	-	-	-	-	-	-
h) Profit on sale of Biotech Business Unit (net of tax) (f-g)	738	-	-	738	-	-
i) Net Profit/(Loss) from discontinuing operations (e+h)	745	147	(50)	892	(79)	323

Particulars	(Rs. in lakhs)	
	As at 30.9.2016	As at 31.3.2016
		Unaudited
A Assets	-	2,502
B Liabilities	-	739

6. The Company has entered into an Asset Purchase Agreement (APA) dated July 27, 2016 for purchase of Trademarks on assignment/perpetual license basis and other assets specified in the said APA from Sun Pharmaceutical Industries Limited (including its subsidiary, Sun Pharma Laboratories Limited) for a consideration of Rs.4,100 lakhs (excluding value of specified inventories on closing to be acquired at agreed price). The closing date being October 21, 2016, no effect of the aforesaid APA has been given in the financial result for the current quarter.

7. Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited

CT. Renganathan
Managing Director
Mumbai, 21st October, 2016